BioInvent International
Andres McAllister, MD PhD, currently serves as the Chief Medical Officer at BioInvent International AB since June 2017 and operates as a self-employed Medical Consultant since February 2016. Prior experience includes the role of Chief Scientific Officer at Debiopharm International SA from 2004 to September 2015, focusing on oncology and infectious diseases, and developing preclinical programs in collaboration with external institutions. Additional roles encompassed Non-Executive Board Member at Immunexpress Inc., Director of R&D at IDM-Biotech, and Senior Virologist at BioMérieux-Pierre Fabre, among others. Andres McAllister's educational background includes a PhD in Virology/Immunology from Université Paris Cité and a Medical Degree from Universidad del Rosario, alongside significant training in vaccine research at the University of California, San Francisco.
This person is not in any offices
BioInvent International
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.